Samsung Biologics (207940) Earnings: 2Q Operating Profit Surges 71%, Beating Estimates

Samsung Biologics on Smartkarma

Analyst coverage on Samsung Biologics by Tina Banerjee on Smartkarma indicates a positive trend for the company. In one report, titled “Samsung Biologics (207940 KS): Gaining Momentum on New Approval and Contract Wins; Hold Shares,” Samsung Biologics secured a significant $1.1B contract, contributing to 40% of the expected 2023 revenue. Additionally, FDA approval for the Stelara biosimilar Pyzchiva further adds to the company’s achievements.

In another insightful report, “Samsung Biologics (207940 KS): Mixed 1Q24 Result; Order Book Swells; New Drug Approval in Europe,” Samsung Biologics surpassed sales and net profit estimates for the first quarter of 2024. Despite a minor operating profit miss, the company’s strong order book of over $12B and approval for a new biosimilar in Europe paint a promising future for Samsung Biologics.

A look at Samsung Biologics Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on Smartkarma Smart Scores, Samsung Biologics has a strong long-term outlook. With a high Growth score of 5, the company is set to expand and develop rapidly in the future. Additionally, Samsung Biologics scores well on Resilience and Momentum, with scores of 4, indicating its ability to withstand market fluctuations and its current positive market trend. However, the company’s Value score is lower at 2, suggesting that it may be slightly overvalued. The Dividend score of 1 indicates that Samsung Biologics does not heavily focus on distributing dividends to its shareholders.

Samsung Biologics Co., Ltd. is a company that focuses on the manufacturing of bio-healthcare products. They are involved in the development, refinement, and distribution of biopharmaceutical products. With strong scores in Growth, Resilience, and Momentum, Samsung Biologics shows promise for future growth and resilience in the market. Investors may need to consider the company’s slightly lower Value score and minimal focus on dividends when making investment decisions regarding Samsung Biologics.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma